Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28867399 | 0.78 | ALDH1A1 (0.33) | KMT2AHSD17B10HPGDPOLBACHE | |
| SCHEMBL11197289 | 0.76 | CHRM2 (0.44) | KMT2AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL10333096 | 0.75 | TDP1 (0.35) | KMT2AHSD17B10PTGS2POLBMAPT | |
| SCHEMBL11857807 | 0.71 | PKM (0.38) | CYP2C9KMT2AHSD17B10HPGDPOLB | |
| SCHEMBL8881481 | 0.70 | MCHR1 (0.43) | KMT2AHPGDACHEMAPTRAB9A | |
| SCHEMBL8868904 | 0.70 | MEN1 (0.52) | CYP3A4CYP2C9CYP2C19KMT2AHSD17B10 | |
| SCHEMBL11480751 | 0.70 | GABRA1 (0.36) | KMT2AHPGDTAAR1 | |
| SCHEMBL23734864 | 0.68 | MTNR1A (0.50) | KMT2APTGS2POLBMAPTRAB9A | |
| SCHEMBL188509 | 0.68 | TAAR1 (0.57) | HPGDPOLBMAPTTAAR1 | |
| SCHEMBL6221028 | 0.67 | CYP1A2 (0.61) | CYP3A4CYP2C9KMT2AHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572907-B2 | Methods and compounds for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1717242-A1 | Polynucleotide synthesis | Agilent Technologies, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060247430-A1 | Methods and compounds for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247430-A1 | Methods and compounds for polynucleotide synthesis | POLN, POLRMT, POLM | CYP3A4 4189/4885CYP2C9 4403/4885CYP2C19 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.